What is HC Wainwright’s Estimate for MNMD FY2029 Earnings?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Investment analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Mind Medicine (MindMed) in a note issued to investors on Friday, January 31st. HC Wainwright analyst P. Trucchio forecasts that the company will earn $2.84 per share for the year. HC Wainwright currently has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share.

Other equities research analysts have also issued research reports about the stock. Leerink Partnrs upgraded shares of Mind Medicine (MindMed) to a “strong-buy” rating in a research note on Friday, October 11th. Chardan Capital assumed coverage on shares of Mind Medicine (MindMed) in a research note on Friday, December 20th. They issued a “buy” rating and a $20.00 price objective for the company. Evercore ISI assumed coverage on shares of Mind Medicine (MindMed) in a research note on Tuesday, January 28th. They issued an “outperform” rating and a $23.00 price objective for the company. Leerink Partners assumed coverage on shares of Mind Medicine (MindMed) in a research note on Monday, October 14th. They issued an “outperform” rating and a $20.00 price objective for the company. Finally, Oppenheimer reiterated an “outperform” rating and issued a $20.00 price objective on shares of Mind Medicine (MindMed) in a research note on Tuesday, December 17th. Ten analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $26.33.

Mind Medicine (MindMed) Trading Up 10.9 %

MNMD opened at $8.17 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.00 and a quick ratio of 9.00. Mind Medicine has a fifty-two week low of $3.85 and a fifty-two week high of $12.22. The firm has a market capitalization of $599.12 million, a PE ratio of -3.62 and a beta of 2.59. The company’s 50-day moving average is $7.26 and its 200 day moving average is $6.90.

Mind Medicine (MindMed) (NASDAQ:MNMD) last posted its earnings results on Thursday, November 7th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. During the same quarter last year, the business posted ($0.53) earnings per share.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC bought a new position in Mind Medicine (MindMed) in the 3rd quarter worth approximately $58,000. Sanctuary Advisors LLC bought a new position in Mind Medicine (MindMed) in the 3rd quarter valued at $91,000. Foundations Investment Advisors LLC bought a new position in Mind Medicine (MindMed) in the 4th quarter valued at $91,000. Stoneridge Investment Partners LLC bought a new position in Mind Medicine (MindMed) in the 3rd quarter valued at $93,000. Finally, SG Americas Securities LLC bought a new position in Mind Medicine (MindMed) in the 3rd quarter valued at $93,000. 27.91% of the stock is owned by institutional investors.

Insider Transactions at Mind Medicine (MindMed)

In related news, insider Dan Karlin sold 6,643 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $7.43, for a total value of $49,357.49. Following the completion of the transaction, the insider now directly owns 338,013 shares of the company’s stock, valued at approximately $2,511,436.59. This trade represents a 1.93 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert Barrow sold 19,106 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $7.43, for a total transaction of $141,957.58. Following the completion of the transaction, the chief executive officer now directly owns 526,666 shares of the company’s stock, valued at approximately $3,913,128.38. This trade represents a 3.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,022 shares of company stock worth $208,203 in the last quarter. Insiders own 2.26% of the company’s stock.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.